Market Research Logo

Global Primary Immunodeficiency Diseases Treatment Market 2017-2021

Global Primary Immunodeficiency Diseases Treatment Market 2017-2021

About Primary Immunodeficiency Diseases Treatment

Primary immunodeficiency diseases or PIDDs are disorders where part of the body's immune system is missing or not functioning properly. They weaken the body's immune system, making the patient susceptible to infections and other health problems. Treatment is palliative and includes boosting the immune system, thereby helping the patient live a normal life. The major drug classes used for the treatment and management of the disease are immunoglobulins, antibiotics, and others.

Technavio’s analysts forecast the global primary immunodeficiency diseases treatment market to grow at a CAGR of 6.13% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global primary immunodeficiency diseases treatment market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Primary Immunodeficiency Diseases Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • CSL Behring
  • Grifols
  • Pfizer
  • Shire
Other prominent vendors
  • Abbott
  • ADMA Biologics
  • Astellas
  • AstraZeneca
  • Baxter
  • Bayer
  • Biocon
  • Bristol-Myers Squibb
  • BDI Pharma
  • Bharat Serums and Vaccines
  • Eli Lilly
  • GlaxoSmithKline
  • Hualan Biological Engineering
  • Kedrion Biopharma
  • LFB Group
  • Lupin Pharmaceuticals
  • Mylan
  • Novartis
  • Octapharma
  • Sanofi
  • Sanquin
  • Takeda Pharmaceutical Company
  • Valneva
  • Wockhardt
Market driver
  • Growing number of fractionating units
  • For a full, detailed list, view our report
Market challenge
  • High cost of treatment
  • For a full, detailed list, view our report
Market trend
  • Shift of manufacturing facilities to low-cost regions
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Primary Immunodeficiency Diseases Treatment Market 2017-2021

Technavio recognizes the following companies as the key players in the global primary immunodeficiency diseases treatment market: CSL Behring, Grifols, Pfizer, and Shire.

Other Prominent Vendors in the market are: Abbott, ADMA Biologics, Astellas, AstraZeneca, Baxter, Bayer, Biocon, Bristol-Myers Squibb, BDI Pharma, Bharat Serums and Vaccines, Eli Lilly, GlaxoSmithKline, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, Lupin Pharmaceuticals, Mylan, Novartis, Octapharma, Sanofi, Sanquin, Takeda Pharmaceutical Company, Valneva, and Wockhardt.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is shift of manufacturing facilities to low-cost regions. Shift of manufacturing and fractionating centers to low-cost regions have increased in the last decade due to economic advantages. This will improve the supply of immunoglobulins in developing countries and will improve the overall distribution channel.”

According to the report, one driver in the market is growing number of fractionating units. Fractionation is a crucial step involved in the manufacture of immunoglobulins. This step involves the separation of immunoglobulins and other blood protein from plasma. The capacity of fractionating units is increasing. Data estimates suggest that in between 2013 and 2016, the capacity increased by 39.5%. This increased capacity is primarily due to the instalment of new fractionating units or expansion of existing fractionating units.

Further, the report states that one challenge in the market is high cost of treatment. The immunoglobulin therapy is the primary regimen in the treatment of PIDDs. However, the cost of treatment is high because of direct costs associated with the production of immunoglobulins. The plasma donors have to be paid. Further, high costs associated with processing, fractionating, and freeze-drying also affect the price of the final product. All these factors contribute to the overall pricing of the product, making the product expensive for the end-user.

Companies Mentioned

CSL Behring, Grifols, Pfizer, Shire, Abbott, ADMA Biologics, Astellas, AstraZeneca, Baxter, Bayer, Biocon, Bristol-Myers Squibb, BDI Pharma, Bharat Serums and Vaccines, Eli Lilly, GlaxoSmithKline, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, Lupin Pharmaceuticals, Mylan, Novartis, Octapharma, Sanofi, Sanquin, Takeda Pharmaceutical Company, Valneva, and Wockhardt.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
      • Table Features of PIDDs
      • Table Signs and symptoms of PI
      • Table PIDDs classification based on affected immune system
      • Table Diagnosis and treatment of PI
  • Market landscape
    • Market overview
      • Table Global PIDDs treatment market 2016-2021 ($ millions)
      • Table Opportunity analysis of global PIDDs treatment market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline landscape
    • Table Pipeline analysis of vendors in global PIDDs treatment market
    • Table Key clinical trials
  • Market segmentation by therapy
    • Table Market segmentation by therapy
    • Immunoglobulin therapy
      • Table Global PIDDs treatment market by immunoglobulin therapy 2016-2021 ($ millions)
    • Antibiotics
      • Table Global PIDDs treatment market by antibiotics 2016-2021 ($ millions)
      • Table Antibiotic prophylaxis regimens in several PIDDs
    • Others
      • Table Global PIDDs treatment market by others 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Segmentation of global PIDDs treatment market by geography 2016 and 2021
    • Table Global PIDDs treatment market revenue by geography 2016-2021 ($ millions)
    • PIDDs treatment market in Americas
      • Table Market scenario in Americas
      • Table PIDDs treatment market in Americas 2016-2021 ($ millions)
    • PIDDs treatment market in EMEA
      • Table Market scenario in EMEA
      • Table PIDDs treatment market in EMEA 2016-2021 ($ millions)
    • PIDDs treatment market in APAC
      • Table Market scenario in APAC
      • Table PIDDs treatment market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Fractionation capacities of key vendors
    • Market challenges
      • Table Various side effects associated with immunoglobulin therapy
      • Table Factors contributing to overall cost of production for IVIG
      • Table Detailed information regarding processes required for TGA approval
  • Market trends
    • Shift of manufacturing facilities to low-cost regions
      • Table Fractionating capacities globally in 2007 and 2012
    • Financial aid to plasma donors
  • Vendor landscape
    • Table Competitive structure analysis of global PIDDs treatment market 2016
    • Table Competitive factors of global PIDDs treatment market
    • Table Market penetration of various PIDDs treatment manufacturers globally 2016
    • Table Strategic success factors of companies in global PIDDs treatment market
  • Key vendor analysis
    • CSL Behring
      • Table CSL Behring: Key highlights
      • Table CSL Behring: Strength assessment
      • Table CSL Behring: Strategy assessment
      • Table CSL Behring: Opportunity assessment
    • Grifols
      • Table Grifols: Key highlights
      • Table Grifols: Strength assessment
      • Table Grifols: Strategy assessment
      • Table Grifols: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Shire
      • Table Shire: Key highlights
      • Table Shire: Strength assessment
      • Table Shire: Strategy assessment
      • Table Shire: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report